Biosimilars for breast cancer treatment - European Medical Journal

Continue

Biosimilars for breast cancer treatment

Oncology
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges in the manufacture, development and approval of biosimilars for breast cancer treatment.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.